CLVS Clovis Oncology Inc

Price (delayed)

$4.92

Market cap

$514.46M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.69

Enterprise value

$987.83M

Highlights
CLVS's EPS is up by 49% YoY and by 16% from the previous quarter
CLVS's net income is up by 19% YoY and by 9% from the previous quarter
Clovis Oncology's revenue has increased by 5% YoY but it has decreased by 2.7% QoQ
CLVS's gross profit is down by 3.1% since the previous quarter but it is up by 2.9% year-on-year
The equity has plunged by 74% YoY and by 39% from the previous quarter
The quick ratio has contracted by 41% YoY and by 15% from the previous quarter

Key stats

What are the main financial stats of CLVS
Market
Shares outstanding
104.56M
Market cap
$514.46M
Enterprise value
$987.83M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
3.21
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
6.17
Earnings
Revenue
$160.01M
EBIT
-$307.79M
EBITDA
-$299.48M
Free cash flow
-$232.56M
Per share
EPS
-$3.69
Free cash flow per share
-$2.23
Book value per share
-$2.11
Revenue per share
$1.53
TBVPS
$4.04
Balance sheet
Total assets
$548.84M
Total liabilities
$769.88M
Debt
$664.3M
Equity
-$221.04M
Working capital
$79.28M
Liquidity
Debt to equity
-3.01
Current ratio
1.46
Quick ratio
1.23
Net debt/EBITDA
-1.58
Margins
EBITDA margin
-187.2%
Gross margin
74.6%
Net margin
-210.1%
Operating margin
-173.9%
Efficiency
Return on assets
-56.6%
Return on equity
N/A
Return on invested capital
-42.3%
Return on capital employed
-81.9%
Return on sales
-192.4%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

CLVS stock price

How has the Clovis Oncology stock price performed over time
Intraday
1.86%
1 week
3.36%
1 month
-13.53%
1 year
-15.03%
YTD
2.5%
QTD
-15.17%

Financial performance

How have Clovis Oncology's revenue and profit performed over time
Revenue
$160.01M
Gross profit
$119.4M
Operating income
-$278.19M
Net income
-$336.16M
Gross margin
74.6%
Net margin
-210.1%
The operating margin has grown by 29% YoY and by 5% from the previous quarter
The operating income has increased by 26% YoY and by 8% from the previous quarter
Clovis Oncology's net margin has increased by 23% YoY and by 6% from the previous quarter
CLVS's net income is up by 19% YoY and by 9% from the previous quarter

Growth

What is Clovis Oncology's growth rate over time

Valuation

What is Clovis Oncology stock price valuation
P/E
N/A
P/B
N/A
P/S
3.21
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
6.17
CLVS's EPS is up by 49% YoY and by 16% from the previous quarter
The equity has plunged by 74% YoY and by 39% from the previous quarter
CLVS's P/S is 100% below its 5-year quarterly average of 1266.9 and 6% below its last 4 quarters average of 3.4
Clovis Oncology's revenue has increased by 5% YoY but it has decreased by 2.7% QoQ

Efficiency

How efficient is Clovis Oncology business performance
CLVS's ROS is up by 24% YoY and by 7% from the previous quarter
The company's return on assets rose by 8% YoY and by 7% QoQ
Clovis Oncology's return on invested capital has increased by 7% QoQ

Dividends

What is CLVS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CLVS.

Financial health

How did Clovis Oncology financials performed over time
The company's total assets is 29% lower than its total liabilities
The current ratio has contracted by 41% YoY and by 13% from the previous quarter
The quick ratio has contracted by 41% YoY and by 15% from the previous quarter
The equity has plunged by 74% YoY and by 39% from the previous quarter
The company's debt to equity rose by 37% YoY and by 26% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.